ArticleJournal of Cancer2022

Safety and anti-tumor effects of vismodegib in patients with refractory advanced gastric cancer: A single-arm, phase-II trial.

Ryul Kim et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.